Benjamin F. Edwards & Company Inc. Purchases 371 Shares of Enovis Co. (NYSE:ENOV)

Benjamin F. Edwards & Company Inc. grew its position in shares of Enovis Co. (NYSE:ENOV) by 28.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,691 shares of the company’s stock after purchasing an additional 371 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Enovis were worth $76,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in ENOV. American Century Companies Inc. lifted its stake in Enovis by 78.6% during the second quarter. American Century Companies Inc. now owns 1,511,871 shares of the company’s stock worth $68,337,000 after purchasing an additional 665,208 shares during the last quarter. Diamond Hill Capital Management Inc. lifted its stake in Enovis by 14.5% during the second quarter. Diamond Hill Capital Management Inc. now owns 2,786,034 shares of the company’s stock worth $125,929,000 after purchasing an additional 352,116 shares during the last quarter. Boston Partners lifted its stake in Enovis by 206.5% during the first quarter. Boston Partners now owns 295,969 shares of the company’s stock worth $18,455,000 after purchasing an additional 199,411 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Enovis by 100.6% during the first quarter. Janus Henderson Group PLC now owns 378,020 shares of the company’s stock worth $23,606,000 after purchasing an additional 189,584 shares during the last quarter. Finally, Hantz Financial Services Inc. purchased a new position in shares of Enovis in the second quarter worth about $8,547,000. Institutional investors own 98.45% of the company’s stock.

Enovis Stock Up 0.7 %

Shares of NYSE:ENOV opened at $43.66 on Friday. Enovis Co. has a 1 year low of $39.98 and a 1 year high of $65.03. The company has a market cap of $2.44 billion, a PE ratio of -29.10 and a beta of 1.92. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.26 and a quick ratio of 1.08. The stock’s 50-day moving average is $44.42 and its 200 day moving average is $49.39.

Enovis (NYSE:ENOV) last posted its earnings results on Wednesday, August 7th. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.03. Enovis had a positive return on equity of 4.06% and a negative net margin of 4.73%. The firm had revenue of $525.20 million for the quarter, compared to the consensus estimate of $525.99 million. During the same quarter in the prior year, the business earned $0.61 EPS. The business’s revenue for the quarter was up 22.6% on a year-over-year basis. Sell-side analysts anticipate that Enovis Co. will post 2.7 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ENOV shares. Needham & Company LLC decreased their price objective on Enovis from $82.00 to $65.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Evercore ISI decreased their price objective on Enovis from $70.00 to $62.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Finally, JPMorgan Chase & Co. decreased their price objective on Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Enovis currently has a consensus rating of “Moderate Buy” and an average price target of $69.13.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.